TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Social phobic ambulatory subjects, defined according to DSM-IV criteria.~* Must be capable of giving informed consent and can comply with the study requirements.~* Women of childbearing potential must agree to acceptable method of birth control.~Exclusion criteria:~* Primary diagnosis within the past 6 months of other psychiatric conditions such as major depression or another anxiety disorder.~* Use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type.~* Subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months.~* Subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance dependence (other than nicotine).~* Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG) findings.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid in Pediatric Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children undergoing elective cardiac surgery with cardiopulmonary bypass~Exclusion Criteria:~* neonate born within 1 month~* preoperative inotropes~* preoperative mechanical ventilation~* preexisting coagulation disorder~* reoperation within 48 hours~* significant liver or kidney disease~* known allergy to TXA

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (Type: ACTIVE_COMPARATOR): 50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit.
- Placebo (Type: PLACEBO_COMPARATOR): same volume of normal saline was given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Histologically or cytologically confirmed R/M HNSCC of the oral cavity, oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapy~2. Documented progressive disease based on investigator assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) following receipt of at least two cycles of cisplatin or carboplatin administered for R/M disease~3. Measurable disease according to RECIST~4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~Exclusion criteria:~1. Progressive disease within three months of completion of curatively intended treatment for locoregionally advanced or metastatic HNSCC~2. Any other than one previous platinum based systemic regimen given for R/M disease~3. Prior treatment with epidermal growth factor receptor (EGFR)-targeted small molecules~4. Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib (BIBW 2992) (Type: EXPERIMENTAL): Once daily
- Methotrexate (Type: ACTIVE_COMPARATOR): Weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Patient Turning for Reducing Hospital Acquired Pressure Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (\>18 years of age)~* Admission to Intensive Care Unit~Exclusion Criteria:~* Children (\<18 years of age)~* Adhesive allergy~* Physical limitation for sensor application

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment - Optimal Turning (Type: EXPERIMENTAL): All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
- Control - Standard Care (Type: ACTIVE_COMPARATOR): All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vocal Warm-up and Respiratory Muscle Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 20-60.~* No occurence of speech therapy simultaneously to the intervention~Exclusion Criteria:~* Professional voice use in another activity;~* Frequent use of alcohol and tobacco;~* Influenza and/or upper respiratory tract infections (eg, rhinitis, sinusitis, pharyngitis) during the period of participation in the research.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Vocal Warm-up (Type: EXPERIMENTAL): Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
- Respiratory Muscle Training (Type: EXPERIMENTAL): Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:-~* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study.~* Male or female, age 18 years or older at the time of signing informed consent.~* Type 2 diabetes mellitus diagnosis.~* Treatment with either 1 or 2 oral antidiabetic medications.~* Current member of a commercial or Medicare health plan with pharmacy benefits.~* Recorded HbAlc value within the last 90 days prior to randomization.~* Further intensification with an additional antidiabetic oral or injectable medication is indicated to achieve glycemic target at the discretion of the study physician according to approved labelling.~Exclusion Criteria:~* Previous randomization in this study~* Treatment with more than 2 oral antidiabetic medications, oral semaglutide, or any injectable medication in a period of 30 days before the day of eligibility assessment. Temporary/emergency use of any type of insulin is allowed, as is prior insulin treatment for gestational diabetes.~* Contraindications to semaglutide according to the Food and Drug Administration approved label.~* Female who is pregnant, breastfeeding or intends to become pregnant~* Participation in another clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Participants will receive semaglutide subcutaneously (s.c.) in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
- Standard of care (Type: ACTIVE_COMPARATOR): Participants will receive standard of care in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Carvedilol on Health Outcomes in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* primary hospitalization with heart failure and LVEF \< 40%~* patient informed consent has been obtained~* absence of pulmonary congestion~* age \> 18 years~Exclusion Criteria:~* End-stage renal or hepatic disease~* Acute myocardial infarction as primary diagnosis during index hospitalization~* Life-expectancy \< 6-months~* Contraindication to beta blocker use~* Current beta-blocker therapy~* Planned bypass or valve surgery during index hospitalization

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients have moderate allergic rhinitis (itching and nasal obstruction, watery nasal discharge, sneezing and congestion )with a minimum total nasal symptom score 7 point~2. These patients do not have the respiratory disease such as tuberculosis, nasal polyps.~3. These patients do not have the history of disease: heart disease, kidney disease, liver disease, epilepsy, high blood pressure and severe asthma.~4. These patients are not pregnant or breastfeeding.~5. These patients have normal BMI and vital signs.~Exclusion Criteria:~1. Those who have taken anti-coagulant and anti-platelet aggregation medications.~2. Those who get serious side effects from Loratadine and ginger allergy.~3. Communication problems especially listening and interview.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ginger extract (Type: EXPERIMENTAL): Drug
- Loratadine (Type: ACTIVE_COMPARATOR): Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities.~* Male or female between 18 and 70 years of old.~* 19≤Body mass index(BMI)≤30kg/m\^2.~* No participate in any clinical trial at least 3 months.~* Diagnosed impaired fasting glucose(IFG) and impaired glucose tolerance(IGT) or Diabetes.~* In visit 1, 5.60mmol/L≤Fasting plasma glucose(FPG)\<8.0mmol/L; in visit 2, 6.1≤FPG\<8.0mmol/L or 7.8≤2-hour postprandial plasma glucose(2h-PPG) \<17mmol/L.~* Females in child-bearing period should be given birth control.~* No severe disease about heart, lung and kidney.~Exclusion Criteria:~* Type 1 diabetes~* Diabetes patients with previously treated or untreated FPG ≥ 8 mmol/L or 2-h PPG ≥ 17 mmol/L;~* Women of childbearing potential who are pregnant, breastfeeding or intend to become pregnant or are not using adequate contraceptive methods.~* Those who are allergic to study drugs~* Unable to cooperate~* Abnormal liver function, ALT and AST are more than 2 times of the normal upper limit~* Renal injury, blood creatinine ≥133 µmol/L~* Poor blood pressure control, systolic blood pressure SBP≥160mmHg and/or diastolic blood pressure DBP≥95mmHg~* Patients with chronic gastrointestinal diseases (pancreatitis, inflammatory bowel disease) and history of intestinal surgery~* Patients with severe heart disease, such as heart failure, unstable angina pectoris, acute myocardial infarction~* Chronic hypoxic diseases such as emphysema, pulmonary heart disease~* Having obvious diseases of the blood system~* Persons with tumor diseases~* Endocrine diseases, such as hyperthyroidism and hypercortisolism~* Mental illness, abuse of alcohol, drugs or other substances~* Persons with long-term oral or intravenous corticosteroid hormones therapy~* Having stress conditions such as surgery, severe trauma, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Berberine Hydrochloride group (Type: EXPERIMENTAL): 2/day, 16 weeks
- Bifidobacterium group (Type: EXPERIMENTAL): 2/day, 16 weeks
- Berberine Hydrochloride and Bifidobacterium group (Type: EXPERIMENTAL): 2/day, 16 weeks
- placebo (Type: PLACEBO_COMPARATOR): bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observation of the Use of QUTENZA™ in Standard Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1. The investigator has decided to treat the patient with QUTENZA as part of provision of standard care for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain~* 2. The patient is willing and able to comply with protocol requirements for the duration of study participation~Exclusion Criteria:~* 1. The neuropathic painful areas are located only on the face, above the hairline of the scalp, and/or in proximity to mucous membranes~* 2. The patient has a history of Type I or Type II diabetes mellitus~* 3. The patient has a diagnosis of any major psychiatric disorder or evidence of cognitive impairment including dementia that, in the opinion of the investigator, may interfere with patient's ability to complete study evaluations~* 4. The patient has received any prior treatment with QUTENZA patches, including blinded patches administered as part of a clinical trial~* 5. The patient has hypersensitivity to capsaicin (i.e. chilli peppers or over-the-counter \[OTC\] capsaicin products), any QUTENZA excipients or adhesives, or local anesthetics~* 6. The patient has participated in any other clinical study or received an investigational drug within 30 days prior to Screening Visit~* 7. The patient currently engages in any active substance abuse or has a history of chronic substance abuse within 1 year prior to the Screening Visit; or any prior chronic substance abuse (including alcoholism) likely to re-occur during the study period as judged by the investigator~* 8. The patient, in the opinion of the investigator, is not suitable to participate in this NIS for any reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with QUTENZA (Type: None): Patients with Peripheral Neuropathic Pain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects with primary DSM-IV diagnosis of GAD, as confirmed by the MINI structured interview.~* Historical failure to respond optimally to a GAD treatment~Exclusion Criteria:~* Current primary DSM-IV (Diagnostic and Statistical Manual of Mental Disorders 4th edition) diagnosis of major depressive disorder with or without seasonal pattern, dysthmic disorder, depressive disorder NOS (not otherwise specified), social phobia, panic disorder with or without agoraphobia, post traumatic stress disorder, dissociative disorder, borderline personality disorder, obsessive-compulsive disorder, antisocial personality disorder, as defined in the DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision).~* Past and/or current DSM-IV diagnosis of schizophrenia, schizoaffective disorder, other psychotic disorders, bipolar disorders (I or II), factitious disorder or cognitive disorder (including delirium, dementia, and amnestic disorder).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 2 (Type: PLACEBO_COMPARATOR): None
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Pervasive Developmental Disorders (Autistic Disorder, Rett's Disorder, Childhood Disintegrative Disorder, Asperger's Disorder, or Pervasive Development Disorder not Otherwise Specified) by Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), Axis I criteria~* with a total score of \>=30 on the Childhood Autism Rating Scale (CARS)~* receiving treatment as an out-patient~* healthy on the basis of a physical examination, electrocardiogram (ECG), and medical history at start of the study.~Exclusion Criteria:~* Diagnosis of schizophrenia or other psychotic disorders by DSM-IV criteria~* seizure during 3 months prior to study initiation or currently being treated with more than one anticonvulsant drug~* history of tardive dyskinesia (a complication of neuroleptic therapy involving involuntary movements of facial muscles)~* neuroleptic malignant syndrome (a rare psychotropic-drug reaction, which may be characterized by confusion, reduced consciousness, high fever or pronounced muscle stiffness)~* known hypersensitivity, intolerance, or unresponsiveness to risperidone.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 6 months and ≤ 14 years~* Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum or mixed with non-falciparum species~* Asexual P. falciparum parasitaemia ≥ 100,000/uL and ≤500,000/uL~* Haemoglobin ≥5.0 g/dL~* Parents/guardians agree to hospitalize the child for the length of treatment (3 days) and bring the patient for planned follow-up visits at day 7, 14, 21, 28, 35, 42~* Signed consent from the guardian/parents~Exclusion Criteria:~* Body weight ≤ 5 kg~* Severe malaria or signs of severe malaria as defined by WHO Guidelines 2013~* History of hypersensitivity or contraindication to quinine or artesunate~* A clear history of adequate antimalarial treatment in the preceding 24 hours with drugs expected to be effective~* Presence of intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the patient treatment or results of the study~* Participation in another clinical trial

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- IV artesunate (Type: EXPERIMENTAL): Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)
- IV quinine (Type: ACTIVE_COMPARATOR): Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete